下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity in Preclinical Model
BetterLife先导药物(BETR-001)在临床前模型中促进结构神经可塑性

GlobeNewswire ·  {{timeTz}}

VANCOUVER, British Columbia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd generation non-hallucinogenic psychedelic analogs for the treatment of neuropsychological disorders, is pleased to announce it has obtained positive results from a preclinical neural plasticity study of BETR-001 in cortical rat neurons, as part of its collaboration with the laboratory of Dr. Argel Aguilar-Valles at Carleton University's (Carleton) Department of Neuroscience ( BETR-001 (2-bromo-LSD, formerly TD-0148A) is a non-hallucinogenic derivative of lysergic acid diethylamide (LSD).

温哥华,不列颠哥伦比亚省,2022年2月15日(Global Newswire)--BetterLife Pharma Inc.(以下简称“BetterLife”或“公司”)(CSE:BETR/OTCQB:BETRF/FRA:NPAU),一家专注于2-甲氧基苯丙胺的开发和商业化的新兴生物技术公司(CSE:BETR/OTCQB:BETRF/FRA:NPAU)发送作为与卡尔顿大学(Carleton University)神经科学系Argel Aguar-Valles博士实验室合作的一部分,用于治疗神经心理障碍的新一代非致幻迷幻类似物BETR-001(2-bromo-LSD,前身为TD-0148A)高兴地宣布,它在大鼠皮层神经元的临床前神经可塑性研究中取得了积极的结果(BETR-001(2-bromo-LSD,前身为TD-0148A)是一种非致幻的lyseron衍生物

Atrophy of neurons in the brain plays a critical role in pathophysiology of depression and related disorders. Increased structural plasticity in the brain neurons (mainly prefrontal cortex) has been linked to the sustained antidepressant effects of ketamine and other psychedelic compounds. BetterLife had previously shown the anti-depressant properties of BETR-001 in a rodent chronic variable stress model. The current study demonstrates that treatment of rat embryonic cortical neurons with BETR-001 increases the structural complexity of neurons (dendrite growth and complexity) and therefore, provides evidence of neural plasticity activity of BETR-001. In certain measurements of structural plasticity in neurons, BETR-001 performs better than ketamine in this model.

脑神经元萎缩在抑郁症及相关疾病的病理生理学中起重要作用。脑神经元(主要是前额叶皮质)结构可塑性的增加与氯胺酮和其他迷幻化合物的持续抗抑郁作用有关。BetterLife之前在啮齿动物慢性可变压力模型中显示了BETR-001的抗抑郁特性。目前的研究表明,BETR-001处理大鼠胚胎皮质神经元增加了神经元的结构复杂性(树突生长和复杂性),从而为BETR-001的神经可塑性活性提供了证据。在神经元结构可塑性的某些测量中,BETR-001在该模型中的表现优于氯胺酮。

"We are very pleased with these preclinical results as they confirm that BETR-001, an LSD analog, retained the anti-depressant and neural plasticity activity of LSD but without causing hallucination. This is the first evidence that BETR-001 can promote structural plasticity in the prefrontal cortex neurons and gives us confidence on its therapeutic potential in depression and related disorders," stated BetterLife's Chief Executive Officer, Dr. Ahmad Doroudian.

BetterLife公司首席执行官艾哈迈德·多鲁迪安博士说:“我们对这些临床前结果感到非常高兴,因为它们证实了LSD类似物BETR-001保留了LSD的抗抑郁和神经可塑性活性,但不会引起幻觉。这是BETR-001可以促进前额皮质神经元结构可塑性的第一个证据,并使我们对其治疗抑郁症和相关疾病的潜力充满信心。”

Dr. Argel Aguilar-Valles commented, "We are pleased to collaborate with the BetterLife team in demonstrating for the first time the ability of 2-bromo-LSD (BETR-001) to promote neural plasticity. LSD and other psychedelic drugs have been shown to have anti-depressant effects, and non-hallucinogenic derivatives of these drugs such as BETR-001 represent a promising alternative."

阿盖尔·阿吉拉尔-瓦勒斯博士评论说:“我们很高兴与BetterLife团队合作,首次展示了2-溴-LSD(BETR-001)促进神经可塑性的能力。LSD和其他迷幻药物已被证明具有抗抑郁作用,而这些药物的非致幻衍生物,如BETR-001,是一种很有前途的替代药物。”

About BetterLife Pharma

关于BetterLife Pharma

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.

BetterLife制药公司是一家新兴的生物技术公司,主要致力于开发和商业化两种化合物BETR-001和BETR-002,用于治疗神经精神和神经疾病。

BETR-001 (formerly TD-0148A), which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore, can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent for composition and method of use covers treatment of depression, cluster headaches, post-traumatic stress disorder and other neuro-psychiatric and neurological disorders.

Betr-001(前身为TD-0148A)正在进行临床前和IND支持研究,是一种正在开发中的非致幻和非受控LSD衍生物,其独特之处在于它不受监管,因此可以自我给药。BetterLife用于BETR-001的合成专利消除了管理障碍,其正在申请的组合物和使用方法专利涵盖治疗抑郁症、丛集性头痛、创伤后应激障碍和其他神经精神和神经紊乱。

BETR-002 (formerly TD-010), which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife's pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.

Betr-002(前身为TD-010)是基于厚朴树皮中的有效抗焦虑成分和厚朴酚,正在进行临床前和IND研究。BetterLife正在申请的使用方法和配方专利涵盖了治疗焦虑症相关疾病,包括对苯二氮类药物的依赖。

BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.

BetterLife还拥有一种治疗新冠肺炎等病毒感染的候选药物,目前正在寻找进一步发展的战略替代药物。

For further information, please visit BetterLife Pharma.

欲了解更多信息,请访问BetterLife Pharma。

About the Department of Neuroscience at Carleton University

关于卡尔顿大学神经科学系

Carleton Neuroscience has an international reputation for research on stress and its effects on brain functioning and mental health. The department has an interdisciplinary approach to understanding the emergence, prevention and treatment of mental and physical disorders.

卡尔顿神经科学在研究压力及其对大脑功能和心理健康的影响方面享有国际声誉。该部门有一个跨学科的方法来理解精神和身体疾病的出现、预防和治疗。

For more information, please visit .

有关更多信息,请访问。

Contact Information

联系信息

David Melles, Investor Relations Manager
Email: David.Melles@blifepharma.com
Phone: 1-778-887-1928

投资者关系经理大卫·梅尔斯(David Melle)
电子邮件:David.Melle@blifepharma.com
电话:1-778-887-1928

Cautionary Note Regarding Forward-Looking Statements

有关前瞻性陈述的注意事项

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

没有任何证券交易所对本新闻稿内容的充分性或准确性进行审查或承担责任。本新闻稿包含与产品开发、许可、商业化和法规遵从性问题有关的前瞻性陈述,以及其他非历史事实的陈述。前瞻性陈述通常由诸如“将”、“可能”、“应该”、“预期”、“期望”和类似的表达方式来识别。本新闻稿中除历史事实陈述外的所有陈述均为前瞻性陈述,涉及风险和不确定因素。不能保证这些陈述将被证明是准确的,实际结果和未来事件可能与这些陈述中预期的大不相同。可能导致实际结果与本公司预期大相径庭的重要因素包括未能满足相关证券交易所的条件以及本公司不时提交给证券监管机构的文件中详细说明的其他风险。提醒读者,在准备任何前瞻性信息时使用的假设可能被证明是不正确的。由于许多已知和未知的风险、不确定性和其他因素,其中许多不是公司所能控制的,事件或情况可能导致实际结果与预测的结果大不相同。提醒读者不要过度依赖任何前瞻性信息。这些信息,尽管管理层在准备时认为是合理的, 可能被证明是不正确的,实际结果可能与预期的大不相同。本新闻稿中包含的前瞻性陈述明确受本警告性声明的限制。本新闻稿中包含的前瞻性陈述是截至本新闻稿发布之日作出的,公司将根据适用法律的明确要求,公开更新或修改任何包含的前瞻性陈述。


本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。